The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Tenofovir disoproxil 245 mg film coated tablets



Accord Healthcare Ireland Ltd.PA2315/208/001

Main Information

Trade NameTenofovir disoproxil 245 mg film coated tablets
Active SubstancesTenofovir disoproxil
Dosage FormFilm-coated tablet
Licence HolderAccord Healthcare Ireland Ltd.
Licence NumberPA2315/208/001

Group Information

ATC CodeJ05AF Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF07 tenofovir disoproxil

Status

License statusWithdrawn
Withdrawn Date29/11/2023
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Summary of Product Characteristics, section 4.2).
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back